Business
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the
About this update from Biofrontera Inc.
[{"type":"text","content":"WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021. Revenue for the fourth quarter of 2021 is anticipated to be in the range of approximately $9.1 million to $9.2 million, an increase of approximately 7% over the same quarter last year. Revenue for the full year 2021 is anticipated to be in the range of $24.1 million to $24.2 million, an increase of approximately 27% over full year 2020. \"I am proud of the hard work by our sales teams across the country. Our team has performed well during the fourth quarter, with revenue meeting our expectations,\" said Erica Monaco, CEO of Biofrontera Inc. “Our performance is a testament to the strong market positioning of our portfolio products. Despite the ongoing challenges due to the COVID-19 pandemic, we have achieved a return to topline growth in 2021. We are excited about the opportunities ahead to continue building long-term value for our shareholders.” The preliminary unaudited revenue results described in this press release are estimates only and are based only on currently available information. Our final revenue results upon completion of our closing procedures may vary from the preliminary revenue estimates. We expect to issue our full audited financial results for the fourth quarter and fiscal year 2021 in March 2022. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com. Forward-Looking Statements Certain statements in this press release may constitute \"forward-looking statements\" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, the Company’s estimated revenue for the fourth quarter and year ended December 31, 2021, the p...